Roivant Sciences Operating Income decreased by 10.7% to -$339.15M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 23.6%, from -$274.38M to -$339.15M. Over 3 years (FY 2021 to FY 2024), Operating Income shows an upward trend with a -9.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Higher operating income indicates strong operational efficiency and pricing power, while a decline suggests rising costs or weakening demand.
Operating income is the profit realized from a company's core business operations after deducting all operating expenses...
A standard benchmark for operational performance; peers are compared based on operating margin percentages.
operating_income| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$154.39M | -$684.43M | -$246.02M | -$266.80M | -$282.31M | -$280.77M | -$378.08M | $0.00 | -$276.41M | -$213.89M | $5.13B | $0.00 | -$102.24M | -$341.71M | -$274.38M | -$284.97M | -$284.92M | -$306.23M | -$339.15M |
| QoQ Change | — | -343.3% | +64.1% | -8.4% | -5.8% | +0.5% | -34.7% | +100.0% | — | +22.6% | >999% | -100.0% | — | -234.2% | +19.7% | -3.9% | +0.0% | -7.5% | -10.7% |
| YoY Change | — | — | — | — | -82.9% | +59.0% | -53.7% | +100.0% | +2.1% | +23.8% | >999% | — | +63.0% | -59.8% | -105.4% | — | -178.7% | +10.4% | -23.6% |